Adicet Bio

ADICET BIO INC

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio Inc

Press Releases

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

ACET

Agenus

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atossa Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Entera Bio

EXoZymes

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Immix Biopharma

Opus Genetics

Macrogenics

OKYO Pharma

Oncolytics Biotech

Ovid Therapeutics

Pelthos Therapeutics

AVITA Medical

Surrozen

TScan Therapeutics

Instil Bio

Tevogen Bio Holdings

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Guggenheim

HC Wainwright & Co.

Wedbush

Jones Trading

Aceto Corporation

Comments

Adicet Bio

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL